Peptide RX

back to claim graph

proof receipt / fold

CHRNA7 WT

Structure prediction with public confidence context.

grade B status complete receipt ff5ff7293706 proof 67%

what this node claims

CHRNA7 WT

Structure prediction with public confidence context.

Open source surface

vertical proof spine

  1. 01 CHRNA7 WT fold / grade B / 62% 2 debt
  2. 02 AlphaFold metrics / CHRNA7 alphafold metric / grade B / 70% 1 debt
  3. 03 Initial digest — CHRNA7 finding / grade C / 47% 1 debt
  4. 04 fold.complete timeline event / grade C / 55%
  5. 05 CHRNA7 target / grade B / 70% 1 debt

evidence / risk instrument

50%
thin proof
structure evidence gates risk export lineage 50
visible debt pressure 47%
78%structureusable
pLDDT 78.33
55%evidencethin
grade C
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
67%lineageusable
incomplete spine

proof completeness

67% missing candidate, export
  1. 01 target
  2. 02 fold
  3. 03 alphafold metric
  4. 04 candidate
  5. 05 finding
  6. 06 export

Metrics and receipt inputs

confidence band
confident
confidence pct
78.33
coverage available
false
gene
CHRNA7
has structure
true
pae available
false
plddt avg
78.33
sequence length
0
variant
WT

AlphaFold metrics visual

Confident backbone model

78.3

502 residues / min 28.12 / max 96.94 / source alphafold db

PAE matrix for linked target
Very high 38.4% 193 residues / >=90
Confident 38.2% 192 residues / 70-89
Low 7.4% 37 residues / 50-69
Very low 15.9% 80 residues / <50

usable fold context with explicit model-confidence limits

Near-complete coverage / observed 502 of 502 residues.

  • residues 346-430 / mean 37.37
  • residues 1-21 / mean 57.58
  • residues 322-325 / mean 68.91
  • residues 500-502 / mean 62.88
proof debt register

Visible limits, not hidden cleanup.

47%

Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

low computational-only status add independent evidence, challenge result, or witness review before strengthening
medium no candidate yet leave visible until a stronger public receipt resolves it
medium missing PAE/context where AlphaFold DB is not linked attach pLDDT series, PAE matrix, or coverage evidence
high low evidence grade attach graded finding with source-linked evidence
medium missing functional-site annotations link target annotation, GO term, or binding-site context

weakness and challenge edges

What would stop this from becoming stronger.

debt severity export claim strength next proof needed
computational-only status low visible watch add independent evidence, challenge result, or witness review before strengthening
no candidate yet medium visible weakens leave visible until a stronger public receipt resolves it
missing PAE/context where AlphaFold DB is not linked medium visible weakens attach pLDDT series, PAE matrix, or coverage evidence
low evidence grade high blocks weakens attach graded finding with source-linked evidence
missing functional-site annotations medium visible weakens link target annotation, GO term, or binding-site context

what supports it

target has structure prediction target:fc5e5ff4-7348-4d45-85b4-c33c3a8457eb -> fold:fcd130e6-5f75-472b-a4ca-c6e8fc43176e folds_to / B / 0.783

what it supports

measured by AlphaFold confidence context fold:fcd130e6-5f75-472b-a4ca-c6e8fc43176e -> alphafold_metric:fcd130e6-5f75-472b-a4ca-c6e8fc43176e measured_by / B / 0.783
evidence finding attached fold:fcd130e6-5f75-472b-a4ca-c6e8fc43176e -> finding:0278613b-3a1a-47f9-90bb-5f56630a02e1 supports / C / 0.6
timeline records state change fold:fcd130e6-5f75-472b-a4ca-c6e8fc43176e -> timeline_event:26 records / C / 0.5

Research-use boundary

This receipt describes public computational research state. It does not expose raw candidate sequences and does not make a clinical claim.